Skip to content

Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)

Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM) - a Retrospective Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04184193
Enrollment
58
Registered
2019-12-03
Start date
2019-12-03
Completion date
2019-12-23
Last updated
2020-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LAM, Lymphangioleiomyomatosis, Pulmonary Rehabilitation

Brief summary

Data from patients with the orphan disease of lymphangioleiomyomatosis (LAM) which performed a pulmonary Rehabilitation program will be analyzed retrospectively. Data will be taken from the internal data base of the reference Center (Schoen Klinik Berchtesgadener Land, Schoenau, Germany) where These data were collected during clinical routine. Data will be included from the year 2000 until now. A retrospectively matched COPD cohort will be included for comparison.

Interventions

OTHERPulmonary Rehabilitation

Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration

Sponsors

Schön Klinik Berchtesgadener Land
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* confirmed diagnosis of Lymphangioleiomyomatosis * performed a pulmonary Rehabilitation program at the reference center

Exclusion criteria

* missing data * repeated stay for pulmonary Rehabilitation at the reference center

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline 6 Minute walk distance at week 4baseline and week 4the walked distance in meter will be the Primary outcome of the 6 Minute walk test
Change from baseline Quality of life at week 4baseline and week 4the physical and mental health component summary score from the Short Form 36 Health Questionnaire will be recorded. Score range from 0 to 100 with lower scores indicating worse impairment

Secondary

MeasureTime frameDescription
Change from baseline lung function at week 4baseline and week 4forced expiratory volume in 1 second and inspiratory vital capacity will be provided in Liter and percent predicted

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026